Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Complement Activation

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    54 result(s) found for: Complement Activation. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2020-005595-35 Sponsor Protocol Number: CHDR2036 Start Date*: 2021-02-11
    Sponsor Name:Centre for Human Drug Research
    Full Title: A dermal inflammatory challenge study to evaluate complement activation in healthy volunteers
    Medical condition: Inflammation / Complement activation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10018065 - General disorders and administration site conditions 10061218 Inflammation PT
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2019-001440-22 Sponsor Protocol Number: 831 Start Date*: 2019-07-28
    Sponsor Name:Skåne University Hospital
    Full Title: Phase 2, multicenter, randomized, open-label, controlled, 2-arm cross-over study to evaluate the clinical efficacy and safety of a renin inhibitor, aliskiren, compared to an angiotensin converting ...
    Medical condition: C3 glomerulopathy
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-005429-26 Sponsor Protocol Number: CHDR2135 Start Date*: 2021-12-15
    Sponsor Name:Centre for Human Drug Research
    Full Title: Immunological characterization of TLR-7 mediated inflammation and complement activation after prolonged Imiquimod exposure in healthy volunteers
    Medical condition: Inflammation / Complement activation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10018065 - General disorders and administration site conditions 10061218 Inflammation PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002488-40 Sponsor Protocol Number: LIPMAT Start Date*: 2015-11-06
    Sponsor Name:Leiden University Medical Center
    Full Title: The LIPMAT study: Liposomal prednisolone to improve hemodialysis fistula maturation
    Medical condition: Nonmaturation of arteriovenous vascular accesses for hemodialysis.
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004865 10019480 Hemodialysis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005731-67 Sponsor Protocol Number: NLxxxxxxxxxx Start Date*: 2021-07-02
    Sponsor Name:Haaglanden Medisch Centrum
    Full Title: Complement Inhibition: Attacking the Overshooting Inflammation @fter Subarachnoid Hemorrhage - A phase II trial on the safety and efficacy of C1 esterase inhibitor for the acute management of subar...
    Medical condition: Subarachnoid hemorrhage
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004852 10042320 Subarachnoid hemorrhage LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003733-25 Sponsor Protocol Number: CHUBX2013/27 Start Date*: 2014-12-03
    Sponsor Name:CHU de BORDEAUX
    Full Title: Pilot Study related to the effect of clopidogrel on plasmatic soluble CD40 ligand during systemic lupus erythematous
    Medical condition: systemic lupus erythematous
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-005611-16 Sponsor Protocol Number: 52003 Start Date*: 2015-03-16
    Sponsor Name:Academic Medical Center, University of Amsterdam
    Full Title: Effect of Intravenous Administration of C1-inhibitor on Inflammation and Coagulation after Bronchial Instillation of House Dust Mite Allergen and Lipopolysaccharide in Allergic Asthma Patients
    Medical condition: Mild asthmatics with house dust mite allergy
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004855 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-005127-27 Sponsor Protocol Number: CIGE025ENL01T Start Date*: 2015-05-29
    Sponsor Name:UMC Utrecht
    Full Title: Markers of Efficacy of Xolair (Omalizumab) in Chronic Spontaneous Urticaria
    Medical condition: Chronic spontaneous urticaria
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-004486-40 Sponsor Protocol Number: R3918-PNH-2021 Start Date*: 2022-04-04
    Sponsor Name:REGENERON PHARMACEUTICALS, INC.
    Full Title: A RANDOMIZED, OPEN-LABEL, RAVULIZUMAB-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF POZELIMAB AND CEMDISIRAN COMBINATION THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO A...
    Medical condition: Paroxysmal nocturnal hemoglobinuria (PNH)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10055629 Paroxysmal nocturnal hemoglobinuria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing) ES (Ongoing) PL (Ongoing) GR (Ongoing) HU (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003121-42 Sponsor Protocol Number: CHDR1635 Start Date*: 2019-11-28
    Sponsor Name:Enceladus Pharmaceuticals BV
    Full Title: A Phase I-IIa, Open label, Dose Escalating Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Intravenous Pegylated Liposomal Dexamethasone Sodium Phosphate as Monotherapy in Pa...
    Medical condition: Castration resistant prostate cancer with bone metastases.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-004226-28 Sponsor Protocol Number: ATS K016 Start Date*: 2005-01-17
    Sponsor Name:Takeda Pharma GmbH
    Full Title: Effects of Pioglitazone in Patients with Type 2 Diabetes Mellitus and Coronary Heart Disease at High Risk for Cardiovascular Complications
    Medical condition: Type 2 Diabetes mellitus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-003826-10 Sponsor Protocol Number: EAGLE Start Date*: 2014-01-24
    Sponsor Name:IRCCS- Mario Negri Institute
    Full Title: EVALUATING THE MORPHOFUNCTIONAL EFFECTS OF ECULIZUMAB THERAPY IN PRIMARY MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS: A PILOT, SINGLE ARM STUDY IN TEN PATIENTS WITH PERSISTENT HEAVY PROTEINURIA
    Medical condition: Membranoproliferative glomerulonephritis
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-003395-23 Sponsor Protocol Number: HK_VL_08_2014 Start Date*: 2015-01-20
    Sponsor Name:Section for Surgical Pathophysiology, Rigshospitalet
    Full Title: Effect of preoperative intravenous highdose methylprednisolone on quadriceps muscle function, endothelial function, complement activation and glucose homeostasis in patients scheduled for total kne...
    Medical condition: Knee joint arthrosis
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004859 10003416 Arthrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003710-13 Sponsor Protocol Number: NL41820.018.12 Start Date*: 2013-03-21
    Sponsor Name:Academic Medical Center
    Full Title: C1-inhibitor improves efficacy of red blood cell transfusion in patients suffering from autoimmune hemolytic anemia – an open-labeled pilot trial
    Medical condition: AutoImmune Hemolytic Anemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10003825 Autoimmune hemolytic anemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003675-18 Sponsor Protocol Number: ANX005-wAIHA-02 Start Date*: 2021-01-11
    Sponsor Name:Annexon, Inc.
    Full Title: A Phase 2, Open-Label, Repeat Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Proof-of-Concept of Intravenous ANX005 in Subjects with Warm Autoimmune Hemolyti...
    Medical condition: Warm Autoimmune Hemolytic Anemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10003825 Autoimmune hemolytic anemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) CZ (Completed) BG (Completed) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004382-13 Sponsor Protocol Number: DANCE Start Date*: 2019-11-28
    Sponsor Name:IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
    Full Title: A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF CEMDISIRAN (ALN-CC5) FOLLOWING WITHDRAWAL OF CHRONIC ECULIZUMAB THERAPY IN PATIENTS WITH ATYP...
    Medical condition: Atypical Hemolytic Uremic Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10019515 Hemolytic uremic syndrome LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-005855-19 Sponsor Protocol Number: BCX9930-211 Start Date*: 2021-10-11
    Sponsor Name:BioCryst Pharmaceuticals Inc
    Full Title: An Open-Label, Safety, Tolerability, and Proof-of-Concept Study of Oral BCX9930 Therapy in Subjects with Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy, or Primary Membranous Nephropathy
    Medical condition: complement 3 glomerulopathy immunoglobulin A nephropathy primary membranous nephropathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10021263 IgA nephropathy PT
    21.1 10038359 - Renal and urinary disorders 10027170 Membranous nephropathy LLT
    20.0 10038359 - Renal and urinary disorders 10077827 C3 glomerulopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) IT (Prematurely Ended) HU (Completed)
    Trial results: View results
    EudraCT Number: 2020-000140-58 Sponsor Protocol Number: NL7255100000 Start Date*: 2020-07-23
    Sponsor Name:Leiden University Medical Center
    Full Title: Complement Inhibition: Attacking the Overshooting Inflammation @fter Traumatic Brain Injury - A phase II trial on the safety and efficacy of C1 esterase inhibitor Cinryze for the acute management o...
    Medical condition: Severe traumatic Brain Injury (TBI) with GCS < 13
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004863 10060690 Traumatic brain injury LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-001619-21 Sponsor Protocol Number: OPTIMAB Start Date*: 2019-10-07
    Sponsor Name:HOSPITAL UNIVERSITARI DE BELLVITGE- IDIBELL
    Full Title: PILOT STUDY FOR THE OPTIMITZATION OF THE MAINTENANCE DOSE OF ECULIZUMAB ACCORDING TO THE WEIGHT IN ADULT PATIENTS WITH ATYPIC HEMOLYTIC UREMIC SYNDROME
    Medical condition: ATYPICAL HEMOLYTIC UREMIC SYNDROME
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004851 10079841 Atypical hemolytic uremic syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000501-93 Sponsor Protocol Number: BCX9930-201 Start Date*: 2020-09-29
    Sponsor Name:BioCryst Pharmaceuticals Inc
    Full Title: A Phase 2, Open-Label Study to Evaluate the Long-term Safety of Oral BCX9930 in Subjects with Paroxysmal Nocturnal Hemoglobinuria (PNH)
    Medical condition: Paroxysmal Nocturnal Hemoglobinuria (PNH)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10055629 Paroxysmal nocturnal hemoglobinuria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) AT (Completed) DK (Prematurely Ended) IT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 20:41:53 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA